首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

2084865

膽道閉鎖治療市場：依疾病類型、治療方法及地區分類

Biliary Atresia Treatment Market, By Disease Type, By Treatment Type, By Geography

出版日期: 2026年06月19日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，膽道閉鎖治療市場規模將達到 13.2 億美元，到 2033 年將達到 22.2 億美元。預計從 2026 年到 2033 年，該市場將以 7.7% 的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	13.2億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	7.70%	預計金額（2033 年）	22.2億美元

膽道閉鎖是一種嬰兒時期發生的疾病。患童出生後不久，膽管就會發生發炎並阻塞。膽汁是一種由肝臟產生和分泌的消化液。膽汁經由膽管輸送到小腸，幫助消化脂肪。當膽管阻塞時，膽汁會在肝臟中積聚，並開始迅速破壞肝細胞，最終導致肝硬化和肝纖維化。膽管發炎的原因尚不清楚，但可能與感染疾病、毒素或免疫系統問題有關。膽道閉鎖的首發徵兆是黃疸。其他症狀包括尿色深褐色、體重成長困難、大便顏色淺、脾臟腫大。

大多數情況下，膽道閉鎖發生在出生後數週至數月內。這很可能是由於肝外（極少數情況下為肝內）膽管的發炎或纖維化所致。早產兒和新生兒出生時很少發現此病（或在新生兒期可能被忽略）。膽道閉鎖的治療需要肝病專家或外科醫師介入。膽管阻塞的嬰兒需要進行一種稱為「葛西手術」的手術，該手術可使膽汁直接從肝臟流入小腸。術前，醫師會進行造影以確認膽管是否有阻塞。如果沒有阻塞，則無需手術。術後通常會服用預防性抗生素一年，以預防膽管炎。以熊去氧膽酸為主要成分的促膽汁分泌劑也常用於術後治療。營養治療，包括補充脂溶性維生素，對於確保充足的營養以支持生長發育至關重要。即使接受最佳治療，仍有約50%的嬰兒會發展為肝硬化，需要進行肝臟移植。

市場動態

對安全有效藥物研發的需求，以及針對膽道閉鎖的持續臨床試驗，預計將推動全球膽道閉鎖治療市場在預測期內成長。例如，截至2021年10月，甲基甲基黃嘌呤類衍生物Pentoxifylline（PTX）正處於II期臨床試驗階段。該試驗旨在確定PTX是否具有足夠的生物活性，從而值得進一步研究其在膽道閉鎖治療的應用。 PTX計劃作為標準治療（如適用，則為葛西手術）的輔助性治療，口服給藥90天。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）介紹全球膽道閉鎖治療市場的主要公司。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
《全球膽道閉鎖治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球膽道閉鎖治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- 波灣合作理事會（GCC）國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- AstraZeneca plc
- Eisai Co., Ltd.
- Mirum Pharmaceuticals, Inc.
- Pfizer Inc.
- Albireo Pharma, Inc.
- Novartis AG
- Alkem Labs
- Glenmark Pharmaceuticals
分析師意見

第8章

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4779

Biliary Atresia Treatment Market is estimated to be valued at USD 1,320 Mn in 2026 and is expected to reach USD 2,220 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,320 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.70%	2033 Value Projection:	USD 2,220 Mn

Biliary atresia is a disease that affects infants. In this disease, the bile ducts are inflamed and blocked right after the birth. Bile is a digestive fluid that is produced and released by the liver. It travels to the small intestine through the bile ducts, where it helps in digesting fats. As the bile ducts are blocked, bile remains in the liver, where it starts to destroy liver cells rapidly and cause cirrhosis, or scarring of the liver. Reason that causes the inflammation of the ducts is not known, but it may be due to infections, toxins, immune problems. The first sign or symptom of biliary atresia is jaundice. Other symptoms include dark brown urine, difficulty in gaining weight, pale colored stools, and enlarged spleen.

In maximum cases, biliary atresia manifests several weeks to months after birth, probably after inflammation and scarring of the extrahepatic (and occasionally intrahepatic) bile ducts. It is rarely present in premature infants or in neonates at birth (or is unrecognized in neonates). Biliary atresia needs treatment by liver specialists and surgeons. Babies with blocked bile ducts require a surgery, which is called the Kasai procedure. This allows bile to drain directly from the liver into the small intestine. At the start of the surgery, the doctor will perform a cholangiogram to check if bile ducts are blocked. If they're not blocked, the baby won't require the procedure. Prophylactic antibiotics are often prescribed for a year postoperatively in order to prevent ascending cholangitis. Drugs that increase bile production (choleretic agents), consisting of ursodiol about are frequently used postoperatively. Nutritional therapy including supplemental fat-soluble vitamins is essential to ensure adequate intake to support growth. Even with optimal therapy, about 50% of babies develop cirrhosis and require liver transplantation.

Market Dynamics

The need to develop a safe and effective drug and the ongoing clinical trials for biliary atresia are expected to drive the global biliary atresia treatment market growth over the forecast period. For instance, as of October 2021, pentoxifylline (PTX), a methylxanthine derivative, is under phase II of clinical trials. The trial's aim is to determine if PTX has sufficient biological activity against biliary atresia to warrant further study. PTX will be administered orally for 90 days as an adjunct to standard therapy, i.e., the Kasai procedure, if applicable.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biliary atresia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global biliary atresia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biliary atresia treatment market

Market Segmentation

By Disease Type (Revenue, USD Mn, 2021-2033)
Type I
Type II
Type III
By Treatment Type (Revenue, USD Mn, 2021-2033)
Medications
Bile Acids
Antibiotics
Corticosteroids
Surgery
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
AstraZeneca plc
Eisai Co., Ltd.
Mirum Pharmaceuticals, Inc.
Pfizer Inc.
Albireo Pharma, Inc.
Novartis AG
Alkem Labs
Glenmark Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Biliary Atresia Treatment Market, By Disease Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Biliary Atresia Treatment Market, By Treatment Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Bile Acids
  - Antibiotics
  - Corticosteroids
Surgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Biliary Atresia Treatment Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- AstraZeneca plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mirum Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Albireo Pharma, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Alkem Labs
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Glenmark Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views

8. Section

References
Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

膽道閉鎖治療市場規模、佔有率和成長分析：按療法、藥物、階段、給藥途徑、應用、最終用戶和地區分類－2026-2033年產業預測

急性膽囊炎市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、原因、診斷程序、治療方法、最終用戶、地區和競爭格局分類），2021-2031年

FAQ

膽道閉鎖治療市場：依疾病類型、治療方法及地區分類